Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies
Non-small Cell Lung CancerSmall Cell Lung Cancer5 moreThe purpose of this study is to compare two types of care - standard oncology care and standard oncology care with early palliative care (started soon after diagnosis) to see which is better for improving the experience of patients and families with advanced lung and non-colorectal GI cancer. The study will use questionnaires to measure patients' and caregivers' quality of life, mood, coping and understanding of their illness.
Rehabilitation by Effort for Patients With Advanced Bronchial Cancer
Bronchial CancerMalignant MesotheliomaBronchopulmonary cancers or mesothelioma are associated with effort deconditioning due to pathology (chronic inflammation) and also to treatments (surgery, radiotherapy, chemotherapy); it's considerably alters patients quality of life. Investigators want to ensured the feasibility of rehabilitation by effort for these patients.
Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant...
Malignant Pleural MesotheliomaThe objective of this multicentre descriptive analysis is to describe the clinical and biological characteristics of patients who have received Programmed cell death 1 (anti-PD1) / (PDL1) Programmed death-ligand 1 (PDL1) immunotherapy outside of a clinical trial in terms of efficacy and safety.
Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program
Lung CancerGastro-Intestinal Cancer6 moreThis study evaluates physical performance in cancer outpatients during a multimodal therapy. Half of the patients will receive physical exercise und nutrition program in combination with a specially formulated whey protein supplement, while the other half will receive standard care.
Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal...
Peritoneal MesotheliomasReview of the investigators hospital experience in cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) for peritoneal mesotheliomas, using Oxaliplatin as intraperitoneal chemotherapeutic agent.
B-Receptor Signaling in Cardiomyopathy
CarcinomasAmyloidosis37 moreWe hope to determine the importance of different genes (including B receptors) in anthracycline-induced cardiomyopathy. This has important benefits to patients exposed to anthracyclines, as this could help determine whether certain individuals have increased susceptibility to cardiac injury.
Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite
Malignant MesotheliomaPulmonary ComplicationsRATIONALE: Studying samples of body fluid and blood from patients who have been exposed to asbestos or vermiculite in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking for biomarkers to detect mesothelioma early in patients exposed to asbestos or vermiculite.
Molecular Predictors of Pemetrexed and Carboplatin Response in Malignant Pleural Mesothelioma (MPM)...
MALIGNANT PLEURAL MESOTHELIOMAThe aim of the present study is to investigate the molecular predictors of pemetrexed and carboplatin response in tumor samples of a series of MPM patients extracting the DNA and genotyping for the TSER polymorphism.
Observational Prospective Analysis of Biological Characteristics of Mesothelioma Patients
Malignant MesotheliomaThis is an observational prospective analysis of biological characteristics of malignant mesothelioma (MM) patients. Frozen and paraffin-embedded tumor specimens and pleural effusion of patients will be collected and than will be analyzed with the following analyses: 1Purification of Tumour Associated Macrophages (TAM) and tumour cells from pleural effusions. 2.Mass spectrometry analysis of TAMs and tumor cells 3.Co focal microscopy analysis of macrophages, tumour cells and specimens derived from patients.
Validation of the MiCK Assay
MesotheliomaSmall Cell Lung Cancer1 moreTesting Mayo Clinic cancer patients with the results being correlated with prior patient therapy, performance status, and extent of disease.